



J. Serb. Chem. Soc. 89 (3) S102–S124 (2024)

JSCS@tmf.bg.ac.rs • www.shd.org.rs/JSCS Supplementary material

SUPPLEMENTARY MATERIAL TO Synthesis, computational and pharmacological evaluation of novel N-{4-[2-(4-aryl-piperazin-1-yl)ethyl]phenyl}-arylamides

DEANA B. ANDRIĆ¹*, SLADJANA DUKIĆ-STEFANOVIĆ², MIHAJLO J. KRUNIĆ³, IVANA I. JEVTIĆ³, JELENA Z. PENJIŠEVIĆ³, VLADIMIR B. ŠUKALOVIĆ³ and SLAĐANA KOSTIĆ-RAJAČIĆ³

¹University of Belgrade, Faculty of Chemistry, Department of Organic Chemistry, Studentski trg 12-16, 11158 Belgrade, Serbia, ²Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Research site Leipzig, Germany and ³University of Belgrade, ICTM – Department of Chemistry, Njegoševa 12, 11000 Belgrade, Serbia

J. Serb. Chem. Soc. 89 (3) (2024) 291-303

TABLE OF CONTENTS

Spectral data analysis of syntesized derivatives	S104
Fig. S-1. ¹ H-NMR spectrum for 2-hydroxy-N-(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5b)	S107
Fig. S-2. ¹³ C-NMR spectrum for 2-hydroxy-N-(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5b)	S107
Fig. S-3. HRMS spectrum for 2-hydroxy- N -(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5b)	S108
Fig. S-4. ¹ H-NMR spectrum for 2-hydroxy- N -(4-(2-(4-(2.3-	
dichlorophenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5c)	S108
Fig. S-5. ¹³ C-NMR spectrum for 2-hydroxy- <i>N</i> -(4-(2-(4-(2,3-	
dichlorophenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5c)	S109
Fig. S-6. HRMS spectrum for 2-hydroxy-N-(4-(2-(4-(2,3-	
dichlorophenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (5c)	S109
Fig. S-7. ¹ H-NMR spectrum for 6-hydroxy-N-(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (6b)	S109
Fig. S-8. ¹³ C-NMR spectrum for 6-hydroxy-N-(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (6b)	S109
Fig. S-9. HRMS spectrum for 6-hydroxy-N-(4-(2-(4-(2-	
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (6b)	S111
Fig. S-10. ¹ H-NMR spectrum for <i>N</i> -(4-(2-(4-(2.3-dichlorophenyl)piperazin-1-	
yl)ethyl)phenyl)-6-hydroxynicotinamide (6c)	S111
Fig. S-11. ¹³ C-NMR spectrum for <i>N</i> -(4-(2-(4-(2,3-dichlorophenyl)piperazin-	
1-yl)ethyl)phenyl)-6-hydroxynicotinamide (6c)	S112

S102

^{*}Corresponding author. E-mail: deanad@chem.bg.ac.rs

Fig. S. 12 HDMS supertrum for $N(A(2)A(2)$ disbloren hered) ninework 1	
vi)athyl)nhanyl) 6 hydroxyniaetinamide (6)	\$112
E.g. S 12 [H NMD exact sum for 2 (A hydroxymboxyl) $N(A(2)(A)(2)$	5112
rig. S-15. 'H-INIVIK spectrum for 2-(4-inyufoxyphenyi)-/v-(4-(2-(4-(2-	S112
Fig. S 14 $\frac{13}{2}$ NMP exact the for 2 (4 hydroxymbory) $N(4)$ (2 (4 (2	5115
rig. S-14C-Nink spectrum for 2-(4-hydroxyphenyi)-iv-(4-(2-(4-(2-	0112
methoxyphenyl)piperazin-1-yljethyl)phenyl)acetamide ($/$ D)	5115
rig. S-15. HKWIS spectrum for 2-(4-hydroxyphenyl)-/v-(4-(2-(4-(2-	C114
$E_{int} = \sum_{j=1}^{n} \sum_{j=1$	5114
Fig. S-10. H-INMR spectrum for 5-nydroxy-IN-(4-(2-(4-(2-	C114
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)penzamide (8b)	5114
Fig. S-17. "C-NWR spectrum for 3-nydroxy-N-(4-(2-(4-(2-	G115
methoxyphenyl/piperazin-1-yl/ethyl/phenyl/benzamide (δD)	5115
Fig. S-18. HKMS spectrum for 3-nydroxy-IN-(4-(2-(4-(2-	G115
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)penzamide (8b)	5115
Fig. 5-19. 'H-INMR spectrum for 4-nydroxy- <i>N</i> -(4-(2-(4-(2-	0110
methoxyphenyl/piperazin-1-yl/ethyl/phenyl/benzamide (90)	5110
Fig. S-20. 13 C-NMR spectrum for 4-nydroxy- N -(4-(2-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-(4-	0110
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide ($9b$)	\$116
Fig. S-21. HRMS spectrum for 4-hydroxy- N -(4-(2-(4-(2-	011 5
methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (9b)	SIT/
Fig. S-22. Diagram of key receptor $-5a$ (top) and $6a$ (bottom) interactions	G110
observed during 100ns molecular dynamics	S118
Fig. S-23. Diagram of key receptor $-5b$ (top) and $5c$ (bottom) interactions	
observed during 100ns molecular dynamics	S119
Fig. S-24. Diagram of key receptor $-6b$ (top) and $6c$ (bottom) interactions	
observed during 100ns molecular dynamics	S120
Fig. S-25. Diagram of key receptor $-7b$ interactions observed during 100ns	
molecular dynamics	S121
Fig. S-26. ADMET of 3-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-	
yl)ethyl)phenyl)benzamide (8b)	S122
Fig. S-27. ADMET of 4-hydroxy- <i>N</i> -(4-(2-(4-(2-methoxyphenyl)piperazin-1-	
yl)ethyl)phenyl)benzamide (9b)	S123
Fig. S-28. ADMET of aripiprazole	S124

Available online at: http://www.shd.org.rs/JSCS

ANDRIĆ et al

l-(*4*-(2-methoxyphenyl)piperazin-*l*-yl)-2-(4-nitrophenyl)ethan-*l*-one (**2b**): Yield: 74%, oil. ¹H NMR (200 MHz, CDCl₃, δ): 8.25-8.15 (*m*, 2H, ArH), 7.50-7.41 (*m*, 2H, ArH), 7.09-6.84 (*m*, 4H, ArH), 3.87 (*s*, 5H, 3H OCH₃ and 2H CH₂), 3.83 (*d*, J = 5.1, 2H piperazine), 3.71-3.60 (*m*, 2H, piperazine), 3.06-2.95 (*m*, 4H, piperazine). ¹³C NMR (50 MHz, CDCl₃, δ): 167.91, 152.12, 146.89, 142.67, 140.28, 129.90 (2C), 123.73 (3C), 120.00, 118.32, 111.25, 55.32, 50.75, 50.26, 46.23, 43.11, 40.94.

1-(4-(2,3-dichlorophenyl)piperazin-1-yl)-2-(4-nitrophenyl)ethan-1-one (**2c**): Yield: 74%, oil. ¹H NMR (200 MHz, CDCl₃, δ): 8.26-8.16 (*m*, 2H, ArH), 7.51-7.40 (*m*, 2H, ArH), 7.24-7.11 (*m*, 2H, ArH), 6.89 (*dd*, $J_1 = 7.2$, $J_2 = 2.4$, 1H, ArH), 3.86 (*d*, J = 6.7, 4H piperazine), 3.72-3.60 (*m*, 2H, CH₂), 2.98-2.89 (*m*,4H, piperazine). ¹³C NMR (50 MHz, CDCl₃, δ): 168.88, 150.92, 148.10, 142.53, 134.23, 130.81 (2C), 127.60, 125.38, 123.88 (3C), 118.74, 52.03, 50.15, 46.27, 42.63, 40.27.

1-(2-methoxyphenyl)-4-(4-nitrophenethyl)piperazine (**3b**): Yield: 72%, oil. ¹H NMR (200 MHz, CDCl₃, δ): 8.21-8.10 (*m*, 2H, ArH), 7.44-7.35 (*m*, 2H, ArH), 7.08-6.84 (*m*, 4H, ArH), 3.87 (*s*, 3H, OCH₃), 3.13 (*t*, *J* = 4.9, 4H piperazine), 2.99-2.91 (*m*, 2H, CH₂), 2.82-2.65 (*m*, 6H, 4H piperazine and CH₂). ¹³C NMR (50 MHz, CDCl₃, δ): 152.22, 148.36, 146.48, 141.12, 128.98 (2C), 124.14, 123.01 (2C), 120.96, 118.16, 111.13, 59.48, 55.29, 53.29 (2C), 50.54 (2C), 33.90.

1-(2,3-dichlorophenyl)-4-(4-nitrophenethyl)piperazine (**3c**): Yield: 72%, oil. ¹H NMR (200 MHz, CDCl₃, δ): 8.22-8.12 (*m*, 2H, ArH), 7.46-7.33 (*m*, 2H, ArH), 7.22-7.10 (*m*, 2H, ArH), 7.01-6.92 (*m*, 1H, ArH), 3.09 (*t*, *J* = 4.7, 4H piperazine), 2.99-2.92 (*m*, 2H, CH₂), 2.75-2.68 (*m*, 6H, 4H piperazine and CH₂). ¹³C NMR (50 MHz, CDCl₃, δ): 151.14, 147.73, 146.54, 134.05 (2C), 129.54 (2C), 127.48, 124.67, 124.13 (2C), 118.60, 59.34, 53.17(2C), 52.03 (2C), 34.08.

4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)aniline (**4b**): Yield: 93%, oil. ¹H NMR (200 MHz, CDCl₃, δ): 7.07-6.81 (*m*, 6H, ArH), 6.68-6.56 (*m*, 2H, ArH), 3.86 (*s*, 3H, OCH₃), 3.14 (*s*, 4H, piperazine), 2.83-2.68 (*m*, 6H, 4H piperazine and CH₂), 2.66-2.57 (*m*, 2H, CH₂). ¹³C NMR (50 MHz, CDCl₃, δ): 152.71, 144.46, 141.24, 131.00, 130.09 (2C), 123.38, 120.91, 118.14, 115.20 (2C), 103.92, 59.84, 54.48, 52.88 (2C), 51.00 (2C), 33.70.

4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)aniline (4c): Yield: 89%, oil. ¹H NMR (400 MHz, CDCl₃, δ): 8.18-8.12 (*m*, 2H, NH₂), 7.38 (*d*, *J* = 8.4, 2H, ArH), 7.29-7.21 (*m*, 2H, ArH), 6.93 (*d*, *J* = 8.2, 2H, ArH), 6.86 (*t*, *J* = 7.3, 1H, ArH), 3.28-3.16 (*m*, 4H, piperazine), 2.96-2.92 (*m*, 2H, CH₂), 2.76-2.61 (*m*, 6H, 4H piperazine and CH₂). ¹³C NMR (101 MHz, CDCl₃, δ): 151.18, 148.23, 146.52, 129.54 (2C), 127.85 (2C), 123.64, 119.46 (2C), 116.09 (2C), 59.42, 53.54 (2C), 49.14 (2C), 33.43.

2-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (**5b**): Yield: 69%, oil. IR (ATR): 3257, 2933, 2832, 1673, 1593, 1239, 1115, 1022, 752, cm⁻¹. ¹H NMR (500 MHz, CDCl₃, δ): 8.71 (d, J = 9.4, 1H, ArH), 7.65 (d, J = 8.5, 1H, ArH), 7.57 (d, J = 8.5, 1H, ArH), 7.26-7.21 (m, 3H, ArH), 7.04-6.99 (m, 1H, ArH), 6.97-6.91 (m, 2H, ArH), 6.87 (d, J = 9.6, 1H, ArH), 6.59 (t, J = 6.8, 1H, ArH), 3.87 (s, 3H, OCH₃), 3.15 (s, 4H, piperazine), 2.88-2.66 (m, 8H, 4H piperazine and 2CH₂). ¹³C NMR (126 MHz, CDCl₃, δ): 163.70, 160.59, 151.61, 145.49, 139.81, 137.71, 136.34, 136.09, 129.15 (2C), 122.98, 121.86, 120.97, 120.67, 120.11, 118.21, 110.67, 108.08, 60.38, 54.94 (2C), 53.31 (2C), 50.43, 32.81. (+)ESI-HRMS m/z: calculated for [C₂₅H₂₈N₄O₃+H⁺] 433.22342, observed 433.22197.

N-(4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}phenyl)benzamide (**5c**): Yield: 88%, oil. IR (ATR): 3113, 2958, 2814, 1675, 1599, 1268, 1114, 961, 778, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 8.44 (*dd*, J_1 = 7.2, J_2 = 2.1, 1H, ArH), 7.78 (*dd*, J_1 = 6.2, J_2 = 2.3, 1H, ArH), 7.58 (*d*, J = 8.3, 2H, ArH), 7.28-7.25 (*m*, 2H, ArH), 7.21 (*d*, J = 8.1, 2H, ArH), 7.13-7.11 (*m*, 1H, ArH), 6.55 (*t*, J = 6.7, 1H, ArH), 2.97 (*s*, 4H piperazine), 2.72 (*t*, J = 7.8, 2H, CH₂), 2.60-2.55 (*m*, 6H, 4H piperazine and CH₂). ¹³C NMR (126 MHz, DMSO-d6, δ): 162.95, 161.76, 151.60, 144.85, 140.41, 136.74, 136.23, 133.01, 129.56 (2C), 128.83, 126.40, 124.71, 120.52, 120.04, 119.95 (2C), 107.28, 60.00, 53.12 (2C), 51.32 (2C), 32.53. (+)ESI-HRMS *m*/*z*: calculated for [C₂₄H₂₄Cl₂N₄O₂+H⁺] 471.13491, observed 471.13342.

6-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (**6b**): Yield: 86%, oil. IR (ATR): 3118, 2944, 2814, 1673, 1539, 1238, 1133, 1028, 751, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 9.90 (s, 1H, OH), 8.17 (d, J = 2.7, 1H, ArH), 7.94 (dd, $J_1 = 9.6$, $J_2 = 2.6$, 1H, ArH), 7.58 (d, J =8.5, 2H, ArH), 7.17 (d, J = 8.6, 2H, ArH), 6.93-6.89 (m, 2H, ArH), 6.84-6.82 (m, 2H, ArH), 6.38 (d, J = 9.7, 1H, ArH), 3.75 (s, 3H, OCH₃), 2.94 (s, 4H, piperazine), 2.71 (t, J = 7.8, 2H, CH₂), 2.56-2.52 (m, 6H, 4H piperazine and 2H CH₂). ¹³C NMR (126 MHz, DMSO-d6, δ): 162.74, 152.93, 141.68, 139.72, 138.34, 137.34, 135.99, 129.12 (2C), 123.18, 121.91 (2C), 120.67 (2C), 119.53, 118.71, 113.03, 112.32, 60.27, 56.23, 53.36 (2C), 51.01 (2C), 32.58. (+)ESI-HRMS *m/z*: calculated for [C₂₅H₂₈N₄O₃+H⁺] 433.22342, observed 433.22182.

N-(4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)phenyl)-6-hydroxynicotinamide (6c): Yield: 92%, oil. IR (ATR): 3281, 2921, 2809, 1651, 1518, 1255, 1131, 790, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 9.90 (s, 1H, OH), 8.17 (s, 1H), 7.94 (dd, J_1 = 9.7, J_2 = 2.7, 1H, ArH), 7.58 (d, J = 8.2, 2H, ArH), 7.30-7.27 (m, 2H, ArH), 7.18 (d, J = 8.3, 2H, ArH), 7.12 (dd, J_1 = 6.8, J_2 = 2.9, 1H, ArH), 6.38 (d, J = 9.6, 1H, ArH), 3.35 (s, 4H, piperazine), 2.97 (s, 4H, piperazine), 2.71 (t, J = 7.7, 2H, CH₂), 2.60-2.55 (m, 2H, CH₂). ¹³C NMR (126 MHz, DMSO-d6, δ): 162.74, 151.62, 139.71, 138.35, 137.72, 135.93, 132.42, 129.12 (2C), 128.84

ANDRIĆ et al

(2C), 125.94, 124.72, 120.68 (2C), 119.97, 119.53, 113.03, 60.48, 53.14 (2C), 51.34 (2C), 32.56. (+)ESI-HRMS *m/z*: calculated for $[C_{24}H_{24}Cl_2N_4O_2+H^+]$ 471.13491, observed 471.13327.

2-(4-hydroxyphenyl)-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)acetamide (**7b**): Yield: 91%, oil. IR (ATR): 3300, 2953, 2835, 1656, 1513, 1243, 1115, 1022, 754, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 10.00 (*s*, 1H, OH), 7.50 (*d*, *J* = 8.5, 2H), 7.14 (*dd*, *J*₁ = 13.6, *J*₂ = 8.5, 4H), 6.95-6.88 (*m*, 2H), 6.87-6.85 (*m*, 2H), 6.71 (*d*, *J* = 8.5, 2H), 3.76 (*s*, 3H, OCH₃), 3.48 (*s*, 2H, CH₂), 2.96 (*s*, 4H, piperazine), 2.72-2.65 (*m*, 2H, CH₂), 2.57 (*s*, 4H, piperazine), 2.55-2.51 (*m*, 2H, CH₂). ¹³C NMR (126 MHz, DMSO-d6, δ): 169.84, 156.44, 152.38, 141.68, 137.63, 135.56, 130.37 (2C), 129.21 (2C), 126.60, 122.74, 121.25, 119.52 (2C), 118.30, 115.48 (2C), 112.32, 60.27, 55.71, 53.36 (2C), 50.43(2C), 42.92, 32.55. (+)ESI-HRMS *m*/*z*: calculated for [C₂₇H₃₁N₃O₃+H⁺] 446.24382, observed 446.24189.

3-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (**8b**): Yield: 75%, oil. IR (ATR): 3402, 2956, 2828, 1674, 1518, 1239, 1116, 1022, 750, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 10.10 (*s*, 1H, OH), 7.68 (*d*, *J* = 8.1, 2H, ArH), 7.38 (*d*, *J* = 7.6, 1H, ArH), 7.32-7.29 (*m*, 2H, ArH), 7.21-7.17 (*m*, 2H, ArH), 6.98-6.88 (*m*, 5H, ArH), 3.79 (*s*, 3H, OCH₃), 2.97 (*s*, 4H, piperazine), 2.75-2.70 (*m*, 2H, CH₂), 2.58-2.55 (*m*, 6H, 4H piperazine and 2H CH₂). ¹³C NMR (126 MHz, DMSO-d6, δ): 167.43, 159.40, 154.00, 143.29, 139.13, 138.53, 137.68, 131.40, 130.72 (2C), 124.35, 122.86, 122.37 (2C), 121.16, 120.14, 119.91, 116.54, 113.93, 61.88, 57.95, 54.98 (2C), 52.05 (2C), 35.40. (+)ESI-HRMS *m/z*: calculated for [C₂₆H₂₉N₃O₃+H⁺] 432.22817, observed 432.22637.

4-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (**9b**): Yield: 69%, oil. IR (ATR): 3195, 2962, 2829, 1679, 1501, 1244, 1146, 1026, 747, cm⁻¹. ¹H NMR (500 MHz, DMSO-d6, δ): 10.09 (*s*, 1H, OH), 8.24 (*s*, 1H, ArH), 7.49 (*d*, *J* = 8.2, 2H, ArH), 7.18 (*d*, *J* = 8.4, 2H, ArH), 7.10 (*d*, *J* = 8.1, 1H, ArH), 6.94-6.87 (*m*, 6H, ArH), 3.76 (*s*, 3H, OCH₃), 2.96 (*s*, 4H, piperazine), 2.73-2.70 (*m*, 2H, CH₂), 2.58-2.53 (*m*, 6H, 4H piperazine and 2H CH₂). ¹³C NMR (126 MHz, DMSO, δ): 164.49, 161.38, 153.99, 143.27, 138.18, 137.70, 131.57, 131.00 (2C), 124.36, 122.86 (2C), 121.15 (2C), 119.91 (2C), 119.68, 116.82, 113.93, 61.81, 57.32, 55.61 (2C), 52.85 (2C), 34.14. (+)ESI-HRMS *m/z*: calculated for [C₂₆H₂₉N₃O₃+H⁺] 432.22817, observed 432.22709.



Available online at: http://www.shd.org.rs/JSCS

fl (ppm) Fig. S-2. ¹³C-NMR spectrum for 2-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1yl)ethyl)phenyl)nicotinamide (5b)

 

Exact mass	Observed mass	Observed ion type	Error (ppm)
433.22342	433.22197	[M+H]⁺	3.35





Fig. S-4. ¹H-NMR spectrum for *N*-(4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)phenyl)-2-hydroxynicotinamide (**5c**)



Fig. S-5. ¹³C-NMR spectrum for N-(4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)phenyl)-2-hydroxynicotinamide (5c)



Exact mass	Observed mass	Observed ion type	Error (ppm)
471.13491	471.13342	[M+H]⁺	3.16

Fig. S-6. HRMS spectrum for N-(4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)phenyl)-2hydroxynicotinamide (5c)



Fig. S-8. ¹³C-NMR spectrum for 6-hydroxy-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)nicotinamide (**6b**)



Exact mass	Observed mass	Observed ion type	Error (ppm)
433.22342	433.22182	[M+H]+	3.69









Exact mass	Observed mass	Observed ion type	Error (ppm)
471.13491	471.13327	[M+H] ⁺	3.48







Available online at: http://www.shd.org.rs/JSCS



Exact mass	Observed mass	Observed ion type	Error (ppm)
446.24382	446.24189	[M+H]⁺	4.32

Fig. S-15. HRMS spectrum for 2-(4-hydroxyphenyl)-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)acetamide (**7b**)



Fig. S-16. ¹H-NMR spectrum for 3-hydroxy-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1yl)ethyl)phenyl)benzamide (**8b**)





Fig. S-17. ¹³C-NMR spectrum for 3-hydroxy-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (**8b**)



Fig. S-18. HRMS spectrum for 3-hydroxy-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1yl)ethyl)phenyl)benzamide (**8b**)



Fig. S-20. ¹³C-NMR spectrum for 4-hydroxy-*N*-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (**9b**)



Exact mass	Observed mass	Observed ion type	Error (ppm)
432.22817	432.22709	[M+H]⁺	2.50





Fig. S-22. Diagram of key receptor - 5a (top) and 6a (bottom) interactions observed during 100ns molecular dynamics. Aromatic interactions are shown in violet, while hydrogen bonds are green. Interactions maintained for 20% or more of total MD time are considered crucial.



Fig. S-23. Diagram of key receptor -5b (top) and 5c (bottom) interactions observed during 100ns molecular dynamics. Aromatic interactions are shown in violet, while hydrogen bonds are green. Interactions maintained for 20% or more of total MD time are considered crucial.



Fig. S-24. Diagram of key receptor -6b (top) and 6c (bottom) interactions observed during 100ns molecular dynamics. Aromatic interactions are shown in violet, while hydrogen bonds are green. Interactions maintained for 20% or more of total MD time are considered crucial.



Fig. S-25. Diagram of key receptor – **7b** interactions observed during 100ns molecular dynamics. Aromatic interactions are shown in violet, while hydrogen bonds are green. Interactions maintained for 20% or more of total MD time are considered crucial.

Molecule 2			
000			Water Solubility
	LIPO	Log S (ESOL) 0	-5.20
		Solubility	2.72e-03 mg/ml ; 6.30e-06 mol/ll
i.	FLEX SIZE	Class 🥹	Moderately soluble
an	T T	Log S (Ali) 🔛	-5.52
· Show		Solubility	1.29e-03 mg/ml ; 2.99e-06 mol/ll
4		Class 🥹	Moderately soluble
	NSATU POLAR	Log S (SILICOS-IT) 😣	-7.47
		Solubility	1.47e-05 mg/ml ; 3.40e-08 mol/ll
	INSOLU	Class 😣	Poorty soluble
			Pharmacokinetics
MILES COc1ccccc1N1C	CN(CC1)CCc1ccc(cc1)NC(=0)c1cccc(c1)O	GI ab-sorption 0	High
Ph	vsicochemical Properties	BBB permeant 9	Yes
ormula	C26H29N3O3	P-gp substrate 0	Yes
olecular weight.	431.53 g/mol	CYP1A2 inhibitor 9	No
um, heavy atoms	32	CYP2C19 inhibitor 9	Yes
lum, arom, heavy atoms	18	CYP2C9 inhibitor 9	No
raction Csp3	0.27	CYP2D6 inhibitor O	Yes
ium. rotatable bonds	8	CYP3A4 inhibitor 0	Yes
lum. H-bond acceptors	4	Log K. (skin permeation)	-5.7.8 cm/e
lum. H-bond donors	2	coarrig (our pointeauon) -	Doublinger
olar Refractivity	134.73	Liningti 🔒	Ves: 0 violation
PISA 😣	65.04 Å*	Charge	Net fuidation ND-120
	Lipop-hillicity	Gnose G	No; 1 violation: MR>130
og Poly (ILOGP) 😣	3.54	Vebel o	Tes.
og Polw (XLOGP3) 🥹	4.44	Egan 🔮	Tes-
og Poly (WLOGIP) 0	3.07	Muegige V	Tes
og Poly (MLOGP) 0	2.81	Bioavailability Score V	0.55
og Poly (SILICOS-IT)	3.56	00000	Medicinal Chemistry
onsensus Log P	3.48	PAINS	0 allert
0.W	140 - 77 147	Brenk 🥹	0 allert
		Leadlikenes:s 😣	No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5
		Synthetic accessibility 0	2.83



Fig. S-26. ADMET of 3-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (**8b**).



Fig. S-27. ADMET of 4-hydroxy-N-(4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)phenyl)benzamide (9b).

Available online at: http://www.shd.org.rs/JSCS

ANDRIĆ et al.





Available online at: http://www.shd.org.rs/JSCS